Molecular Cancer Therapeutics · 2006 · 35 citations · 18 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerApoptosis RegulationApoptosis ResistanceApoptotic SignalingBladder CancerCell DeathBortezomib TherapyBortezomib-based RegimensCancer Cell ApoptosisProteasome Inhibitor TherapyProteasome InhibitorsTumor Necrosis Factor TherapyTumor Necrosis Factor-mediated ApoptosisVascular Endothelial Growth Factor
In a recent study, we showed that the proteasome inhibitor bortezomib sensitizes human bladder cancer cells to IFN-induced cell death. Here, we characterized the molecular mechanisms underlying the antitumoral effects of the combination in more detail. Bortezomib synergized with IFN-alpha to promote apoptosis via a tumor necrosis factor-related apoptosis-inducing ligand-associated mechanism but did not inhibit production of proangiogenic factors (vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8) in human UM-UC-5 cells. In contrast, exposure to the combination did not increase the levels of apoptosis in human UM-UC-3 cells but did inhibit the production of basic fibroblast growth factor and vascular endothelial growth factor. Studies with tumor xenografts confirmed that combination therapy with bortezomib plus IFN-alpha was effective in both models but that the effects were associated with differential effects on tumor necrosis factor-related apoptosis-inducing ligand-associated apoptosis (predominant in UM-UC-5) versus inhibition of angiogenesis (predominant in UM-UC-3). Together, our results show that combination therapy with IFN-alpha plus bortezomib is effective but can work via different mechanisms (apoptosis versus angiogenesis inhibition) in preclinical models of human bladder cancer.
18
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Julian Adams, Vito J. Palombella, Edward A. Sausville et al. · PubMed · 1999 · 1.5K citations
Medicine, Oncology, Pharmacology +14
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
Aaron T. Ludwig, Jill M. Moore, Yi Luo et al. · Cancer Research · 2004 · 187 citations · Full text
Life Sciences, Immunology, Oncology +17